MDSpire - Takeaway
From the Journals

Tirzepatide Linked to Greater QoL Gains vs Dulaglutide

Both groups improved, with numerically larger gains in patient-reported outcomes following a switch to tirzepatide

Share

  • 1

    The SURPASS-SWITCH trial focused on switching from dulaglutide to tirzepatide.

  • 2

    It was a 40-week, phase 4, randomized, open-label trial.

  • 3

    Participants reported improved emotional well-being with tirzepatide.

  • 4

    Measurements included health-related quality of life and emotional outcomes.

  • 5

    Both groups had improvements, but tirzepatide showed greater gains.

  • 6

    Limitations included the open-label design and participant completion rates.

  • 7

    Study funded by Eli Lilly and Company.

Original Source(s)

Tirzepatide Linked to Greater QoL Gains vs Dulaglutide

  • by Conexiant News Staff

  • March 30, 2026

Related Content

Fluvoxamine Reduces Long COVID Fatigue in Trial

A randomized, placebo-controlled trial found the selective serotonin reuptake inhibitor improved fatigue severity vs placebo, while metformin showed no evidence of benefit.

Inside Access, Outside the Rules

Two federal cases highlight alleged misuse of professional roles in health care settings

Side Effects: Variety Is Overrated

The organ you forgot, the cells that age unevenly, the AI that admits ignorance, and the diet advice that sounds wrong but isn't: medicine's next moves are hiding in plain sight.